机构地区:[1]河北省中医院脾胃病二科,石家庄050011 [2]河北中医学院,石家庄050200
出 处:《北京中医药》2020年第3期200-204,共5页Beijing Journal of Traditional Chinese Medicine
基 金:国家中医药管理局重大疑难病中西医临床协作试点项目;国家中医临床研究基地项目;河北省中医药管理局科研计划项目(2020080,2020079,2020084,2020083)。
摘 要:目的探讨化浊解毒方治疗溃疡性结肠炎(UC)的治疗作用及机制。方法120例UC患者按照随机数字表法分为观察组、对照组各60例。观察组予中药化浊解毒方口服,每日1剂,早晚2次温服;对照组予美沙拉嗪肠溶片口服,1.0 g/次,3次/d。2组疗程均4周。对比2组治疗前后Geboes指数、结肠镜下黏膜表现、生活质量评分、疾病活动指数及血清炎性因子IL-8、IL-35水平,凝血指标血清FIB水平,统计治疗后1年内复发情况。结果治疗后,观察组Geboes指数、疾病活动指数及血清炎性因子IL-8水平、凝血指标血清FIB水平均较本组治疗前降低,生活质量评分、血清炎性因子IL-35水平升高(P<0.05);且观察组治疗后疾病活动指数及血清炎性因子IL-8水平、凝血指标血清FIB水平均低于对照组,生活质量评分、血清炎性因子IL-35水平均高于对照组(P<0.05)。与对照组相比,治疗组糜烂、溃疡改善不明显(P>0.05),充血水肿、颗粒样变等肠镜表现改善情况均优于对照组(P<0.05)。治疗结束1年观察组复发率为10.64%,对照组为23.53%,2组差异有统计学意义(P<0.05)。结论化浊解毒方能改善UC患者临床症状,修复肠黏膜病理损伤,降低复发率;其机制可能与调节血清炎性因子IL-8、IL-35和凝血因子FIB水平有关。Objective To explore the therapeutic effect and mechanism of Huazhuo Jiedu Prescription in the treatment of ulcerative colitis(UC).Methods 120 patients with UC were randomly divided into observation group and control group with 60 cases each.The observation group was treated with Huazhuo Jiedu Prescription one bag and twice a day,and the control group was treated with Mesalazide enteric coated tablets 1.0 g each time and 3 times a day.Continuous treatment lasted for 4 weeks as one course in both groups.The improvement of Geboes index,colonoscopy mucosal performance,quality of life score,Mayo activity index,serum inflammatory factors IL-8,IL-35,and coagulation index serum FIB levels before and after treatment were compared,and the recurrence was added up within one year after the treatment finished.Results After the treatment,the Geboes index,Mayo activity index,serum inflammatory factor IL-8 level,and blood coagulation index serum FIB levels in the observation group were lowered more than that before the treatment(P<0.05).Particularly,Mayo activity index,serum inflammatory factor IL-8 level,and blood coagulation index serum FIB levels in the observation group were lower than that of the control group,quality of life scores,serum inflammatory factor IL-35 Level was higher than that of the control group after the treatment(P<0.05).Compared with the control group,the improvement of erosion and ulcer in the treatment group was not significant(P>0.05),and the improvement of intestinal mirror performance such as congested edema and granulomatous changes was better than that of the control group(P<0.05).The relapse rate was 10.64%in the observation group,and 23.53%in the control group one year after treatment(P<0.05).Conclusion Huazhuo Jiedu Prescription can improve the clinical symptoms of UC patients,repair the pathological damage of intestinal mucosa and reduce the recurrence rate.The mechanism may be related to the regulation of serum inflammatory factors IL-8,IL-35 and coagulation factor FIB.
分 类 号:R259[医药卫生—中西医结合]
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...